- Home
- CNEY vs HSCS Comparison
CNEY vs HSCS Comparison
Compare CNEY & HSCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CNEY | HSCS |
|---|---|---|
| Founded | 2009 | 2007 |
| Country | China | United States |
| Employees | N/A | 12 |
| Industry | Major Chemicals | Medical Specialities |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.9M | 6.4M |
| IPO Year | 2019 | N/A |
Fundamental Metrics
Financial Performance| Metric | CNEY | HSCS |
|---|---|---|
| Price | $0.63 | $2.12 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | ★ 3.6M | 47.0K |
| Earning Date | 02-13-2026 | 03-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.31 | $1.63 |
| 52 Week High | $2.95 | $3.93 |
Technical Indicators
Market Signals| Indicator | CNEY | HSCS |
|---|---|---|
| Relative Strength Index (RSI) | 49.28 | 45.55 |
| Support Level | $0.54 | $2.16 |
| Resistance Level | $1.05 | $2.18 |
| Average True Range (ATR) | 0.08 | 0.26 |
| MACD | 0.01 | -0.04 |
| Stochastic Oscillator | 48.99 | 40.79 |
Price Performance
Historical ComparisonAbout CNEY CN Energy Group Inc.
CN Energy Group Inc along with its subsidiaries is a manufacturer and supplier of wood-based activated carbon that is used in pharmaceutical manufacturing, industrial manufacturing, water purification, environmental protection, and food and beverage production and a producer of biomass electricity generated in the process of producing activated carbon. The firm generates a majority of its revenue from Activated carbon.
About HSCS Heart Test Laboratories Inc.
HeartSciences Inc is an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease. Its objective is to improve healthcare by making it a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings. It is developing a suite of AI-ECG diagnostic solutions for use in any healthcare care setting, either via MyoVista Insights cloud-platform using one of the millions of ECG devices currently in clinical use or via MyoVista wavECG Device.